

**Drugs and Therapeutics (D & T) Committee  
Meeting Results  
February 13, 2019**

| <b>Drug Name</b> | <b>Review Type</b>      | <b>Committee Recommendation</b> | <b>Prior Approval Status – Final Determination</b> |
|------------------|-------------------------|---------------------------------|--|
| Aimovig          | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Cimduo           | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Delstrigo        | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Fulphila         | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Orilissa         | New Drug Initial Review | Preferred requires PA           | Preferred requires PA                              |
| Palynziq         | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Pifeltro         | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Symfi            | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Symfi Lo         | New Drug Initial Review | Non-preferred requires PA       | Non-preferred requires PA                          |
| Biktarvy         | New Drug Appeal         | Preferred                       | Preferred  |
| Dupixent         | New Drug Appeal         | Preferred requires PA (Asthma)  | Preferred requires PA (Asthma)                     |
| Eliquis          | PDL Appeal              | Preferred requires PA           | Preferred requires PA                              |